0001829959false3/31/202412/31iso4217:USDiso4217:USDxbrli:sharesxbrli:sharesxbrli:puredocebo:componentiso4217:CADxbrli:sharesutr:Ydocebo:revenue_source00018299592024-03-3100018299592023-12-3100018299592024-01-012024-03-3100018299592023-01-012023-03-310001829959ifrs-full:OrdinarySharesMember2022-12-310001829959ifrs-full:AdditionalPaidinCapitalMember2022-12-310001829959ifrs-full:AccumulatedOtherComprehensiveIncomeMember2022-12-310001829959ifrs-full:RetainedEarningsMember2022-12-3100018299592022-12-310001829959ifrs-full:OrdinarySharesMember2023-01-012023-03-310001829959ifrs-full:AdditionalPaidinCapitalMember2023-01-012023-03-310001829959ifrs-full:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001829959ifrs-full:RetainedEarningsMember2023-01-012023-03-310001829959ifrs-full:OrdinarySharesMember2023-03-310001829959ifrs-full:AdditionalPaidinCapitalMember2023-03-310001829959ifrs-full:AccumulatedOtherComprehensiveIncomeMember2023-03-310001829959ifrs-full:RetainedEarningsMember2023-03-3100018299592023-03-310001829959ifrs-full:OrdinarySharesMember2023-12-310001829959ifrs-full:AdditionalPaidinCapitalMember2023-12-310001829959ifrs-full:AccumulatedOtherComprehensiveIncomeMember2023-12-310001829959ifrs-full:RetainedEarningsMember2023-12-310001829959ifrs-full:OrdinarySharesMember2024-01-012024-03-310001829959ifrs-full:AdditionalPaidinCapitalMember2024-01-012024-03-310001829959ifrs-full:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001829959ifrs-full:RetainedEarningsMember2024-01-012024-03-310001829959ifrs-full:OrdinarySharesMember2024-03-310001829959ifrs-full:AdditionalPaidinCapitalMember2024-03-310001829959ifrs-full:AccumulatedOtherComprehensiveIncomeMember2024-03-310001829959ifrs-full:RetainedEarningsMember2024-03-310001829959docebo:DoceboSpAMember2024-01-012024-03-310001829959docebo:DoceboSpAMember2023-01-012023-12-310001829959docebo:DoceboNAIncMember2024-01-012024-03-310001829959docebo:DoceboNAIncMember2023-01-012023-12-310001829959docebo:DoceboEMEAFZLLCMember2024-01-012024-03-310001829959docebo:DoceboEMEAFZLLCMember2023-01-012023-12-310001829959docebo:DoceboUKMember2024-01-012024-03-310001829959docebo:DoceboUKMember2023-01-012023-12-310001829959docebo:DoceboFranceMember2024-01-012024-03-310001829959docebo:DoceboFranceMember2023-01-012023-12-310001829959docebo:DoceboGermanyMember2024-01-012024-03-310001829959docebo:DoceboGermanyMember2023-01-012023-12-310001829959docebo:DoceboAustraliaPtyLtdMember2024-01-012024-03-310001829959docebo:DoceboAustraliaPtyLtdMember2023-01-012023-12-310001829959docebo:DoceboIrelandLimitedMember2024-01-012024-03-310001829959docebo:DoceboIrelandLimitedMember2023-01-012023-12-310001829959docebo:CirclesCollectiveIncPeerBoardMember2024-01-012024-03-310001829959docebo:CirclesCollectiveIncPeerBoardMember2023-01-012023-12-310001829959docebo:EdugoAIHKLimitedMember2024-01-012024-03-310001829959docebo:EdugoAIHKLimitedMember2023-01-012023-12-310001829959docebo:EdugoAILearningSoftwareLimitedMember2024-01-012024-03-310001829959docebo:EdugoAILearningSoftwareLimitedMember2023-01-012023-12-310001829959ifrs-full:TradeReceivablesMember2024-03-310001829959ifrs-full:TradeReceivablesMember2023-12-310001829959ifrs-full:LandAndBuildingsMemberifrs-full:GrossCarryingAmountMember2023-12-310001829959ifrs-full:OtherPropertyPlantAndEquipmentMemberifrs-full:GrossCarryingAmountMember2023-12-310001829959ifrs-full:GrossCarryingAmountMember2023-12-310001829959ifrs-full:LandAndBuildingsMemberifrs-full:GrossCarryingAmountMember2024-01-012024-03-310001829959ifrs-full:OtherPropertyPlantAndEquipmentMemberifrs-full:GrossCarryingAmountMember2024-01-012024-03-310001829959ifrs-full:GrossCarryingAmountMember2024-01-012024-03-310001829959ifrs-full:LandAndBuildingsMemberifrs-full:GrossCarryingAmountMember2024-03-310001829959ifrs-full:OtherPropertyPlantAndEquipmentMemberifrs-full:GrossCarryingAmountMember2024-03-310001829959ifrs-full:GrossCarryingAmountMember2024-03-310001829959ifrs-full:LandAndBuildingsMemberifrs-full:AccumulatedDepreciationAndAmortisationMember2023-12-310001829959ifrs-full:OtherPropertyPlantAndEquipmentMemberifrs-full:AccumulatedDepreciationAndAmortisationMember2023-12-310001829959ifrs-full:AccumulatedDepreciationAndAmortisationMember2023-12-310001829959ifrs-full:LandAndBuildingsMemberifrs-full:AccumulatedDepreciationAndAmortisationMember2024-01-012024-03-310001829959ifrs-full:OtherPropertyPlantAndEquipmentMemberifrs-full:AccumulatedDepreciationAndAmortisationMember2024-01-012024-03-310001829959ifrs-full:AccumulatedDepreciationAndAmortisationMember2024-01-012024-03-310001829959ifrs-full:LandAndBuildingsMemberifrs-full:AccumulatedDepreciationAndAmortisationMember2024-03-310001829959ifrs-full:OtherPropertyPlantAndEquipmentMemberifrs-full:AccumulatedDepreciationAndAmortisationMember2024-03-310001829959ifrs-full:AccumulatedDepreciationAndAmortisationMember2024-03-310001829959ifrs-full:LandAndBuildingsMember2023-12-310001829959ifrs-full:OtherPropertyPlantAndEquipmentMember2023-12-310001829959ifrs-full:LandAndBuildingsMember2024-03-310001829959ifrs-full:OtherPropertyPlantAndEquipmentMember2024-03-310001829959ifrs-full:GrossCarryingAmountMemberdocebo:FurnituresAndOfficeEquipmentMember2023-12-310001829959ifrs-full:GrossCarryingAmountMemberifrs-full:LeaseholdImprovementsMember2023-12-310001829959ifrs-full:LandAndBuildingsMemberifrs-full:GrossCarryingAmountMember2023-12-310001829959ifrs-full:GrossCarryingAmountMemberdocebo:FurnituresAndOfficeEquipmentMember2024-01-012024-03-310001829959ifrs-full:GrossCarryingAmountMemberifrs-full:LeaseholdImprovementsMember2024-01-012024-03-310001829959ifrs-full:LandAndBuildingsMemberifrs-full:GrossCarryingAmountMember2024-01-012024-03-310001829959ifrs-full:GrossCarryingAmountMemberdocebo:FurnituresAndOfficeEquipmentMember2024-03-310001829959ifrs-full:GrossCarryingAmountMemberifrs-full:LeaseholdImprovementsMember2024-03-310001829959ifrs-full:LandAndBuildingsMemberifrs-full:GrossCarryingAmountMember2024-03-310001829959ifrs-full:AccumulatedDepreciationAndAmortisationMemberdocebo:FurnituresAndOfficeEquipmentMember2023-12-310001829959ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:LeaseholdImprovementsMember2023-12-310001829959ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:LandAndBuildingsMember2023-12-310001829959ifrs-full:AccumulatedDepreciationAndAmortisationMemberdocebo:FurnituresAndOfficeEquipmentMember2024-01-012024-03-310001829959ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:LeaseholdImprovementsMember2024-01-012024-03-310001829959ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:LandAndBuildingsMember2024-01-012024-03-310001829959ifrs-full:AccumulatedDepreciationAndAmortisationMemberdocebo:FurnituresAndOfficeEquipmentMember2024-03-310001829959ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:LeaseholdImprovementsMember2024-03-310001829959ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:LandAndBuildingsMember2024-03-310001829959docebo:FurnituresAndOfficeEquipmentMember2023-12-310001829959ifrs-full:LeaseholdImprovementsMember2023-12-310001829959ifrs-full:LandAndBuildingsMember2023-12-310001829959docebo:FurnituresAndOfficeEquipmentMember2024-03-310001829959ifrs-full:LeaseholdImprovementsMember2024-03-310001829959ifrs-full:LandAndBuildingsMember2024-03-310001829959ifrs-full:CustomerrelatedIntangibleAssetsMemberifrs-full:GrossCarryingAmountMember2023-12-310001829959ifrs-full:GrossCarryingAmountMemberifrs-full:TechnologybasedIntangibleAssetsMember2023-12-310001829959ifrs-full:GrossCarryingAmountMemberifrs-full:BrandNamesMember2023-12-310001829959ifrs-full:CustomerrelatedIntangibleAssetsMemberifrs-full:GrossCarryingAmountMember2024-01-012024-03-310001829959ifrs-full:GrossCarryingAmountMemberifrs-full:TechnologybasedIntangibleAssetsMember2024-01-012024-03-310001829959ifrs-full:GrossCarryingAmountMemberifrs-full:BrandNamesMember2024-01-012024-03-310001829959ifrs-full:CustomerrelatedIntangibleAssetsMemberifrs-full:GrossCarryingAmountMember2024-03-310001829959ifrs-full:GrossCarryingAmountMemberifrs-full:TechnologybasedIntangibleAssetsMember2024-03-310001829959ifrs-full:GrossCarryingAmountMemberifrs-full:BrandNamesMember2024-03-310001829959ifrs-full:CustomerrelatedIntangibleAssetsMemberifrs-full:AccumulatedDepreciationAndAmortisationMember2023-12-310001829959ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:TechnologybasedIntangibleAssetsMember2023-12-310001829959ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:BrandNamesMember2023-12-310001829959ifrs-full:CustomerrelatedIntangibleAssetsMemberifrs-full:AccumulatedDepreciationAndAmortisationMember2024-01-012024-03-310001829959ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:TechnologybasedIntangibleAssetsMember2024-01-012024-03-310001829959ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:BrandNamesMember2024-01-012024-03-310001829959ifrs-full:CustomerrelatedIntangibleAssetsMemberifrs-full:AccumulatedDepreciationAndAmortisationMember2024-03-310001829959ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:TechnologybasedIntangibleAssetsMember2024-03-310001829959ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:BrandNamesMember2024-03-310001829959ifrs-full:CustomerrelatedIntangibleAssetsMember2023-12-310001829959ifrs-full:TechnologybasedIntangibleAssetsMember2023-12-310001829959ifrs-full:BrandNamesMember2023-12-310001829959ifrs-full:CustomerrelatedIntangibleAssetsMember2024-03-310001829959ifrs-full:TechnologybasedIntangibleAssetsMember2024-03-310001829959ifrs-full:BrandNamesMember2024-03-310001829959ifrs-full:GoodwillMember2023-12-310001829959ifrs-full:GoodwillMember2024-01-012024-03-310001829959ifrs-full:GoodwillMember2024-03-310001829959docebo:EmployeeStockOptionsMember2024-01-012024-03-310001829959docebo:EmployeeStockOptionsMember2023-01-012023-03-310001829959docebo:DeferredShareUnitsDSUMember2024-01-012024-03-310001829959docebo:DeferredShareUnitsDSUMember2023-01-012023-03-310001829959docebo:RestrictedStockUnitsMember2024-01-012024-03-310001829959docebo:RestrictedStockUnitsMember2023-01-012023-03-310001829959docebo:EmployeeSharePurchasePlanMember2024-01-012024-03-310001829959docebo:EmployeeSharePurchasePlanMember2023-01-012023-03-310001829959ifrs-full:CostOfSalesMember2024-01-012024-03-310001829959ifrs-full:CostOfSalesMember2023-01-012023-03-310001829959docebo:GeneralAndAdministrativeMember2024-01-012024-03-310001829959docebo:GeneralAndAdministrativeMember2023-01-012023-03-310001829959docebo:SalesAndMarketingExpenseMember2024-01-012024-03-310001829959docebo:SalesAndMarketingExpenseMember2023-01-012023-03-310001829959docebo:ResearchAndDevelopmentExpensesMember2024-01-012024-03-310001829959docebo:ResearchAndDevelopmentExpensesMember2023-01-012023-03-310001829959docebo:ExercisePriceRangeOneMemberifrs-full:BottomOfRangeMember2024-03-310001829959docebo:ExercisePriceRangeOneMemberifrs-full:TopOfRangeMember2024-03-310001829959docebo:ExercisePriceRangeOneMember2024-03-310001829959docebo:ExercisePriceRangeOneMember2024-01-012024-03-310001829959docebo:ExercisePriceRangeTwoMemberifrs-full:BottomOfRangeMember2024-03-310001829959ifrs-full:TopOfRangeMemberdocebo:ExercisePriceRangeTwoMember2024-03-310001829959docebo:ExercisePriceRangeTwoMember2024-03-310001829959docebo:ExercisePriceRangeTwoMember2024-01-012024-03-310001829959docebo:ExercisePriceRangeThreeMemberifrs-full:BottomOfRangeMember2024-03-310001829959ifrs-full:TopOfRangeMemberdocebo:ExercisePriceRangeThreeMember2024-03-310001829959docebo:ExercisePriceRangeThreeMember2024-03-310001829959docebo:ExercisePriceRangeThreeMember2024-01-012024-03-310001829959docebo:ExercisePriceRangeFourMemberifrs-full:BottomOfRangeMember2024-03-310001829959docebo:ExercisePriceRangeFourMemberifrs-full:TopOfRangeMember2024-03-310001829959docebo:ExercisePriceRangeFourMember2024-03-310001829959docebo:ExercisePriceRangeFourMember2024-01-012024-03-310001829959docebo:ExercisePriceRangeFiveMemberifrs-full:BottomOfRangeMember2024-03-310001829959docebo:ExercisePriceRangeFiveMemberifrs-full:TopOfRangeMember2024-03-310001829959docebo:ExercisePriceRangeFiveMember2024-03-310001829959docebo:ExercisePriceRangeFiveMember2024-01-012024-03-310001829959docebo:ExercisePriceRangeOneMemberifrs-full:BottomOfRangeMember2023-03-310001829959docebo:ExercisePriceRangeOneMemberifrs-full:TopOfRangeMember2023-03-310001829959docebo:ExercisePriceRangeOneMember2023-03-310001829959docebo:ExercisePriceRangeOneMember2023-01-012023-03-310001829959docebo:ExercisePriceRangeTwoMemberifrs-full:BottomOfRangeMember2023-03-310001829959ifrs-full:TopOfRangeMemberdocebo:ExercisePriceRangeTwoMember2023-03-310001829959docebo:ExercisePriceRangeTwoMember2023-03-310001829959docebo:ExercisePriceRangeTwoMember2023-01-012023-03-310001829959docebo:ExercisePriceRangeThreeMemberifrs-full:BottomOfRangeMember2023-03-310001829959ifrs-full:TopOfRangeMemberdocebo:ExercisePriceRangeThreeMember2023-03-310001829959docebo:ExercisePriceRangeThreeMember2023-03-310001829959docebo:ExercisePriceRangeThreeMember2023-01-012023-03-310001829959docebo:ExercisePriceRangeFourMemberifrs-full:BottomOfRangeMember2023-03-310001829959docebo:ExercisePriceRangeFourMemberifrs-full:TopOfRangeMember2023-03-310001829959docebo:ExercisePriceRangeFourMember2023-03-310001829959docebo:ExercisePriceRangeFourMember2023-01-012023-03-310001829959docebo:ExercisePriceRangeFiveMemberifrs-full:BottomOfRangeMember2023-03-310001829959docebo:ExercisePriceRangeFiveMemberifrs-full:TopOfRangeMember2023-03-310001829959docebo:ExercisePriceRangeFiveMember2023-03-310001829959docebo:ExercisePriceRangeFiveMember2023-01-012023-03-310001829959docebo:DeferredShareUnitsDSUMember2023-12-310001829959docebo:DeferredShareUnitsDSUMember2024-03-310001829959docebo:RestrictedStockUnitsMember2023-12-310001829959docebo:RestrictedStockUnitsMemberifrs-full:BottomOfRangeMember2024-01-012024-03-310001829959docebo:RestrictedStockUnitsMemberifrs-full:TopOfRangeMember2024-01-012024-03-310001829959docebo:RestrictedStockUnitsMember2024-03-310001829959ifrs-full:ShareOptionsMember2024-01-012024-03-310001829959ifrs-full:ShareOptionsMember2023-01-012023-03-310001829959docebo:SubscriptionRevenueMember2024-01-012024-03-310001829959docebo:SubscriptionRevenueMember2023-01-012023-03-310001829959docebo:ProfessionalServicesRevenueMember2024-01-012024-03-310001829959docebo:ProfessionalServicesRevenueMember2023-01-012023-03-310001829959srt:NorthAmericaMember2024-01-012024-03-310001829959srt:NorthAmericaMember2023-01-012023-03-310001829959docebo:RestOfWorldMember2024-01-012024-03-310001829959docebo:RestOfWorldMember2023-01-012023-03-310001829959ifrs-full:MajorOrdinaryShareTransactionsMember2024-05-092024-05-090001829959ifrs-full:MajorOrdinaryShareTransactionsMember2024-05-09
                                                                                                                                                                    
DOCEBO INC.
UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION
(expressed in thousands of United States dollars)


March 31,December 31,
2024
2023
$$
Assets
Current assets:
Cash and cash equivalents80,648 71,950 
Trade and other receivables (Note 4)
45,046 41,775 
Income taxes receivable752 964 
Prepaids and deposits7,486 5,987 
Net investment in finance lease 81 83 
Contract costs, net
6,893 6,394 
140,906 127,153 
Non-current assets:
Contract costs, net
10,606 10,750 
Net investment in finance lease24 45 
Deferred tax asset
1,705 325 
Right-of-use assets, net (Note 5)
1,624 1,342 
Property and equipment, net (Note 6)
1,959 2,108 
Intangible assets, net (Note 7)
2,206 2,401 
Goodwill (Note 8)
14,045 14,251 
173,075 158,375 
Liabilities
Current liabilities:
Trade and other payables29,201 31,663 
Income taxes payable237 251 
Deferred revenue
76,890 67,268 
Lease obligations (Note 5)
1,807 1,470 
Acquisition holdback payables250  
108,385 100,652 
Non-current liabilities:
Acquisition holdback payables803 1,045 
Deferred revenue
442 617 
Lease obligations (Note 5)
499 639 
Employee benefit obligations
3,305 3,285 
Deferred tax liability
 1,416 
113,434 107,654 
Shareholders’ equity
Share capital (Note 10)
249,274 247,496 
Contributed surplus16,830 13,960 
Accumulated other comprehensive loss
(6,843)(5,946)
Deficit
(199,620)(204,789)
Total equity59,641 50,721 
173,075 158,375 
 
The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.

1

DOCEBO INC.
UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF INCOME AND COMPREHENSIVE INCOME
(expressed in thousands of United States dollars, except per share amounts)
Three months ended
March 31,
2024
2023
$$
Revenue (Note 13)
51,403 41,459 
Cost of revenue (Note 14)
9,926 8,054 
Gross profit41,477 33,405 
Operating expenses
General and administrative 8,155 7,556 
Sales and marketing16,433 16,772 
Research and development10,412 7,377 
Share-based compensation (Note 11)
1,932 1,267 
Foreign exchange (gain) loss
(500)102 
Depreciation and amortization (Note 5, 6 and 7)
818 707 
37,250 33,781 
Operating income (loss)
4,227 (376)
Finance income, net (Note 9)
(545)(2,167)
Other (income) expense, net
(1)183 
Income before income taxes
4,773 1,608 
Income tax (recovery) expense
(396)363 
Net income
5,169 1,245 
Other comprehensive loss (income)
Item that may be reclassified subsequently to income:
Exchange loss (gain) on translation of foreign operations
897 (159)
Comprehensive income
4,272 1,404 
Earnings per share - basic (Note 12)
0.170.04
Earnings per share - diluted (Note 12)
0.170.04
Weighted average number of common shares outstanding - basic (Note 12)
30,319,606 33,153,231 
Weighted average number of common shares outstanding - diluted (Note 12)
31,044,036 34,159,651 

The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.

2

DOCEBO INC.
UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY
(expressed in thousands of United States dollars, except number of shares)

Share capitalContributed surplus
Accumulated other comprehensive loss
Deficit
Total
#$$$$$
Balance, December 31, 2022
32,913,955 268,194 8,458 (9,571)(74,870)192,211 
Exercise of stock options (Note 10 and 11)
8,735 149 (49)— — 100 
Share-based compensation (Note 11)
— — 1,267 — — 1,267 
Release of restricted share units (Note 10 and 11)
5,249 224 (224)— —  
Share issuance under employee share purchase plan (Note 10 and 11)
8,785 322 (58)— — 264 
Comprehensive income
— — — 159 1,245 1,404 
Balance, March 31, 2023
32,936,724 268,889 9,394 (9,412)(73,625)195,246 
Balance, December 31, 2023
30,305,156 247,496 13,960 (5,946)(204,789)50,721 
Exercise of stock options (Note 10 and 11)
13,680 411 (125)— — 286 
Share-based compensation (Note 11)
— — 1,932 — — 1,932 
Share issuance under employee share purchase plan (Note 10 and 11)
6,647 310 (47)— — 263 
Release of restricted share units (Note 10 and 11)
27,626 1,057 (1,057)— —  
Excess tax benefit on stock compensation— — 2,167 — — 2,167 
Comprehensive (loss) income
— — — (897)5,169 4,272 
Balance, March 31, 2024
30,353,109 249,274 16,830 (6,843)(199,620)59,641 


The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.

3

DOCEBO INC.
UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS
(expressed in thousands of United States dollars)

Three months ended
March 31,
2024
2023
$$
Cash flows from (used in) operating activities
Net income
5,169 1,245 
Adjustments to reconcile net income to net cash from (used in) operating activities:
Depreciation and amortization818 707 
Share-based compensation1,932 1,267 
Loss on disposal of asset
19 197 
Unrealized foreign exchange (gain) loss
(1,083)126 
Income tax expense
(396)363 
Finance income, net
(545)(2,167)
Changes in non-cash working capital items:
Trade and other receivables(3,479)(7,265)
Prepaids and deposits(1,605)(2,217)
Contract costs, net
(543)(2,233)
Trade and other payables(1,902)3,178 
Employee benefit obligations106 184 
Deferred revenue9,956 4,434 
Income taxes paid(21) 
Cash from (used in) operating activities
8,426 (2,181)
Cash flows used in investing activities
Purchase of property and equipment(203)(107)
Cash used in investing activities
(203)(107)
Cash flows (used in) from financing activities
Payments received on net investment in finance lease20 44 
Repayment of lease obligations(474)(451)
Interest received426 1,738 
Proceeds from exercise of stock options286 100 
Proceeds from share issuance under employee share purchase plan263 264 
Cash from financing activities
521 1,695 
Net change in cash and cash equivalents during the period
8,744 (593)
Effect of foreign exchange on cash and cash equivalents(46)131 
Cash and cash equivalents, beginning of the period
71,950 216,293 
Cash and cash equivalents, end of the period
80,648 215,831 

The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.

4

DOCEBO INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
March 31, 2024
(expressed in thousands of US dollars, except share amounts)
1Nature of business

Docebo Inc. (“Docebo” or the “Company”), a leading learning platform provider, was incorporated on April 21, 2016 under the Canada Business Corporations Act and is domiciled in Ontario, Canada. The Company’s head office is located at Suite 701, 366 Adelaide Street West, Toronto, Canada, M5V 1R9.

The Company’s shares are listed on both the Toronto Stock Exchange (“TSX”), as of October 8, 2019, and the Nasdaq Global Select Market (“Nasdaq”), as of December 3, 2020, under the stock symbol “DCBO”.

The Company has the following subsidiaries:

Entity nameCountry
Ownership percentage
March 31,
2024
Ownership percentage
December 31, 2023
%%
Docebo S.p.AItaly100100
Docebo NA, Inc.United States100100
Docebo EMEA FZ-LLCDubai100100
Docebo UK LimitedEngland100100
Docebo France Société par Actions Simplifiée (“Docebo France”)France100100
Docebo DACH GmbH (“Docebo Germany”)Germany100100
Docebo Australia Pty Ltd. ("Docebo Australia")Australia100100
Docebo Ireland LimitedIreland100100
Circles Collective Inc. ("PeerBoard")United States100100
Edugo AI HK Limited ("Edugo.AI")Hong Kong100100
Edugo AI Learning Software Limited ("Edugo.AI LS")1
Dubai6060

1Edugo AI Learning Software Limited was incorporated on October 3, 2023. As of March 31, 2024, the value of the identifiable net assets was nil. As such, no non-controlling interest was recognized.

2Basis of preparation

Statement of compliance

The unaudited condensed consolidated interim financial statements (“financial statements”) have been prepared by management using the same accounting policies and methods as those used in the Company’s consolidated financial statements for the year ended December 31, 2023. These unaudited condensed consolidated interim financial statements have been prepared in accordance with IAS 34 – Interim Financial Reporting. Accordingly, certain disclosures normally included in annual financial statements prepared in accordance with IFRS Accounting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”) have been omitted or condensed. These unaudited condensed consolidated interim financial statements should be read in conjunction with the Company’s consolidated financial statements for the year ended December 31, 2023.

These financial statements were approved and authorized for issuance by the Board of Directors of the Company on May 9, 2024.

Use of estimates, assumptions and judgments

The preparation of these financial statements in conformity with IFRS requires management to make estimates, assumptions and judgments that affect the application of accounting policies and the reported amounts of assets and

5

DOCEBO INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
March 31, 2024
(expressed in thousands of US dollars, except share amounts)
liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period. Actual results may differ from those estimates.

Estimates are based on management’s best knowledge of current events and actions the Company may undertake in the future. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

In preparing these financial statements, the significant judgments made by management in applying the Company’s accounting policies and the key sources of uncertainty are the same as those applied and described in the Company’s annual audited consolidated financial statements for the year ended December 31, 2023.

3Summary of material accounting policies

The material accounting policies applied in these financial statements are the same as those applied and described in the Company’s annual audited consolidated financial statements as at and for the year ended December 31, 2023.

4Trade and other receivables

The Company’s trade and other receivables as at March 31, 2024 and December 31, 2023 include the following:
2024
2023
$$
Trade receivables39,038 36,355 
Accrued revenues3,715 3,486 
Tax credits receivable2,081 1,890 
Interest receivable169  
Other receivables43 44 
45,046 41,775 

Included in trade receivables is a provision for expected credit losses of $1,250 as at March 31, 2024 and $1,053 as at December 31, 2023.

5Leases

The Company’s right-of-use assets by class of assets are as follows:
PremisesOthersTotal
$$$
Costs
Balance – December 31, 2023
5,1543325,486
Additions668668
Disposals(236)(236)
Effects of foreign exchange(90)(9)(99)
Balance – March 31, 2024
5,4963235,819

6

DOCEBO INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
March 31, 2024
(expressed in thousands of US dollars, except share amounts)
PremisesOthersTotal
Accumulated amortization
Balance – December 31, 2023
3,8862584,144
Amortization33510345
Disposals(217)(217)
Effects of foreign exchange(75)(2)(77)
Balance – March 31, 2024
3,9292664,195
Carrying value
Net balance – December 31, 2023
1,268741,342
Net balance – March 31, 2024
1,567571,624

The Company’s lease obligations are as follows:
2024
$
Balance – January 12,109 
Additions668 
Disposals(236)
Interest accretion41 
Lease repayments(474)
Effects of foreign exchange198 
Balance -March 31
2,306 
Current1,807 
Non-current499 
2,306 

Expenses incurred for the three months ended March 31, 2024 and 2023 relating to short-term leases and leases of low-value assets were $23 and $38, respectively.


7

DOCEBO INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
March 31, 2024
(expressed in thousands of US dollars, except share amounts)
6Property and equipment
Furniture and office equipmentLeasehold improvementsLand and BuildingTotal
$$$$
Cost
Balance – December 31, 2023
3,598 1,973 348 5,919 
Additions203   203 
Effects of foreign exchange(69)(37)(12)(118)
Balance – March 31, 2024
3,732 1,936 336 6,004 
Accumulated depreciation
Balance – December 31, 2023
2,382 1,328 101 3,811 
Depreciation216 81 3 300 
Effects of foreign exchange(43)(19)(4)(66)
Balance – March 31, 2024
2,555 1,390 100 4,045 
Carrying value
Balance – December 31, 2023
1,216 645 247 2,108 
Balance – March 31, 2024
1,177 546 236 1,959 

7Intangible assets
Acquired
Customer relationshipsTechnologyTrademarksTotal
$$$$
Cost
Balance – December 31, 2023
1,382 2,349 44 3,775 
Effects of foreign exchange(37)(14)(1)(52)
Balance – March 31, 2024
1,345 2,335 43 3,723 
Accumulated amortization
Balance – December 31, 2023
729 601 44 1,374 
Amortization56 117  173 
Effects of foreign exchange(20)(9)(1)(30)
Balance – March 31, 2024
765 709 43 1,517 
Carrying value
Balance – December 31, 2023
653 1,748  2,401 
Balance – March 31, 2024
580 1,626  2,206 

8Goodwill

$
Balance – December 31, 2023
14,251 
Effects of foreign exchange(206)
Balance – March 31, 2024
14,045 

8

DOCEBO INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
March 31, 2024
(expressed in thousands of US dollars, except share amounts)

9Finance income, net

Finance income for the three months ended March 31, 2024 and 2023 is comprised of:
Three months ended March 31,
2024
2023
$$
Interest on acquisition related consideration10 16 
Interest on lease obligations41 59 
Interest income(596)(2,242)
(545)(2,167)

10Share capital
Authorized:
Unlimited common shares with no par value
Issued and outstanding:
Number of shares
Amount
#$
Balance – December 31, 2023
30,305,156 247,496 
Exercise of stock options13,680 411 
Issuance of common shares under employee share purchase plan6,647 310 
Release of restricted share units27,626 1,057 
Balance – March 31, 2024
30,353,109 249,274 


11Share-based compensation

The Company has four components within its share-based compensation plan: stock options, DSUs, RSUs and shares issued pursuant to the ESPP.

Share-based compensation expense associated with each component is as follows for the three months ended March 31:

Three months ended March 31,
2024
2023
$$
Stock options767 566 
DSUs268 229 
RSUs871 437 
ESPP26 35 
1,932 1,267 

The following table presents share-based compensation expense by function for the three months ended March 31:

9

DOCEBO INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
March 31, 2024
(expressed in thousands of US dollars, except share amounts)

Three months ended March 31,
2024
2023
$$
Cost of revenue93 25 
General and administrative1,125 733 
Sales and marketing455 445 
Research and development259 64 
1,932 1,267 

The changes in the number of stock options during the three months ended March 31, 2024 and 2023 were as follows:
2024
2023
Number of optionsWeighted average exercise priceNumber of optionsWeighted average exercise price
#C$#C$
Options outstanding – January 1825,091 28.37 1,349,001 13.60 
Options granted91,361 73.54 207,127 52.38 
Options forfeited(12,630)49.78 (11,915)46.32 
Options exercised(13,680)26.66 (8,735)16.00 
Options outstanding – March 31
890,142 32.73 1,535,478 18.56 
Options exercisable – March 31
516,355 17.76 1,003,393 4.83 

The weighted average fair value of share options granted during the three months ended March 31, 2024 and 2023 was estimated at the date of grant using the Black-Scholes option pricing model using the following inputs:

2024
2023
C$C$
Weighted average stock price valuation$73.54 $52.38 
Weighted average exercise price$73.54 $52.38 
Risk-free interest rate3.58 %2.98 %
Expected life in years4.54.5
Expected dividend yield % %
Volatility57 %65 %
Weighted average fair value of options issued$36.70 $28.26 














10

DOCEBO INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
March 31, 2024
(expressed in thousands of US dollars, except share amounts)
The following table is a summary of the Company’s stock options outstanding as at March 31, 2024:
Options outstandingOptions exercisable
Exercise price rangeNumber outstandingWeighted average remaining contractual life (years)Exercise price rangeNumber exercisable
C$##C$#
0.0001 - 1.09
235,320 2.48
0.0001 - 1.09
235,320 
8.86 - 11.06
23,985 6.74
8.86 - 11.06
21,242 
15.79 - 16.00
170,877 5.52
15.79 - 16.00
131,309 
26.43 - 60.00
333,580 5.62
26.43 - 60.00
113,748 
60.01 - 95.12
126,380 5.36
60.01 - 95.12
14,736 
890,142 4.76516,355 

The following table is a summary of the Company’s stock options outstanding as at March 31, 2023:
Options outstandingOptions exercisable
Exercise price rangeNumber outstandingWeighted average remaining contractual life (years)Exercise price rangeNumber exercisable
C$##C$#
0.0001 - 1.09
784,368 4.21
0.0001 - 1.09
784,368 
8.86 - 11.06
51,811 7.71
8.86 - 11.06
35,126 
15.79 - 16.00
246,312 6.53
15.79 - 16.00
139,060 
26.43 - 60.00
410,075 6.85
26.43 - 60.00
31,646 
60.01 - 95.12
42,912 8.28
60.01 -95.12
13,193 
1,535,478 5.571,003,393 

DSUs

The following table presents information concerning the number of DSUs granted by the Company:
#
DSUs – December 31, 2023
115,576 
Granted (at C$66.82 per unit)
1,212 
DSUs - March 31, 2024
116,788 

RSUs

The following table presents information concerning the number of RSUs granted by the Company:
#
RSUs – December 31, 2023
160,150 
Granted (at C$73.54 per unit)
45,566 
Released (at C$40.30 - $86.38 per unit)
(27,626)
Forfeited (at C$52.15 - $86.38 per unit)
(5,279)
RSUs - March 31, 2024
172,811 






11

DOCEBO INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
March 31, 2024
(expressed in thousands of US dollars, except share amounts)
12Earnings per share

Basic and diluted net income per share for the three months ended March 31 are calculated as follows:
Three months ended March 31,
2024
2023
Net income attributable to common shareholders$5,169 $1,245 
Basic weighted average number of common shares outstanding30,319,606 33,153,231 
Stock options418,285 802,418 
DSUs116,147 89,043 
RSUs189,998 114,959 
Diluted weighted average number of common shares outstanding31,044,036 34,159,651 
Basic earnings per common share$0.17 $0.04 
Diluted earnings per common share$0.17 $0.04 

For the three months ended March 31, 2024, there were 8,339 stock options (three months ended March 31, 2023 – 23,782 stock options) that were not taken into account in the calculation of diluted earnings per share because their effect was anti-dilutive.

13Revenue and related balances

Disaggregated revenue

The Company derives its revenues from two main sources, subscription to its SaaS application, and professional services revenue, which includes professional and premium support services such as initial implementation, project management, training, and integration.

The following table presents a disaggregation of revenue for the three months ended March 31:
Three months ended March 31,
2024
2023
$$
Subscription revenue47,890 38,844 
Professional services3,513 2,615 
51,403 41,459 

14Cost of revenue

The following table represents cost of revenue for the three months ended March 31:
Three months ended March 31,
2024
2023
$$
Employee salaries and benefits4,960 4,586 
Web hosting fees1,460 1,177 
Third party service fees3,202 2,123 
Other304 168 
9,926 8,054 


12

DOCEBO INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
March 31, 2024
(expressed in thousands of US dollars, except share amounts)
15Employee compensation

The total employee compensation comprising salaries and benefits, inclusive of tax credits, and excluding share-based compensation for the three months ended March 31, 2024 was $28,580 (2023 - $26,068).
Employee compensation costs were included in the following expenses for the three months ended March 31, 2024 and 2023 is as follows:    
Three months ended March 31,
2024
2023
$$
Cost of revenue4,960 4,586 
General and administrative4,089 3,510 
Sales and marketing11,802 11,967 
Research and development7,729 6,005 
28,580 26,068 

16Related party transactions

Key management personnel are those persons having the authority and responsibility for planning, directing and controlling activities of the Company, directly or indirectly. Key management personnel includes the Company’s Directors and Officers.

Compensation awarded to key management personnel for the three months ended March 31, 2024 and 2023 is as follows:
Three months ended March 31,
2024
2023
$$
Salaries and benefits790 946 
Share-based compensation1,043 1,106 
1,833 2,052 

17Financial instruments and risk management

Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from deposits with banks and outstanding receivables. The Company trades only with recognized, creditworthy third parties. Due to the Company’s diversified customer base, there is no particular concentration of credit risk related to the Company’s trade and other receivables. Trade and other receivables are monitored on an ongoing basis to ensure timely collection of amounts.

The carrying values of cash and cash equivalents, trade and other receivables, and trade and other payables approximate fair values due to the short-term nature of these items or being carried at fair value. The risk of material change in fair value is not considered to be significant. The Company does not use derivative financial instruments to manage this risk.

During the three months ended March 31, 2024, there were no transfers of amounts between levels in the fair value hierarchy.

18Segment information

13

DOCEBO INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
March 31, 2024
(expressed in thousands of US dollars, except share amounts)

The Company reports segment information based on internal reports used by the chief operating decision maker (“CODM”) to make operating and resource allocation decisions and to assess performance. The CODM is the Chief Executive Officer. The CODM makes decisions and assesses performance of the Company on a consolidated basis such that the Company is a single reportable operating segment.

The following tables present details on revenues derived in the following geographical locations for the three months ended March 31, 2024 and 2023.

Three months ended March 31,
2024
2023
$$
North America39,130 31,477 
Rest of World
12,273 9,982 
51,403 41,459 

19Subsequent events

On May 9, 2024, the Company announced an intention to renew the NCIB, and repurchase and cancel up to 1,764,037 of its common shares, representing approximately 10% of its public float as of May 6, 2024, over the 12-month period commencing May 20, 2024, and ending no later than May 19, 2025.

14